Table 1.
Recent studies comparing the outcomes of AML patients between haplo-SCT and other transplantation modalities.
| Authors | Pros | Pt. N. | Age* | Remission status | SCT type | 2–4 aGVHD | cGVHD | Relapse | NRM | LFS | OS | GRFS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ciurea SO, et al. (4) | No | 192 | NA | CR2 (20%/35%)/Rel (34%/16%) | Haplo-SCT | 16%/19% | 30%/34% at 3 yr | 44%/58% at 3 yr | 14%/9% at 3 yr | NA | 45%/46% at 3 yr | NA |
| 1982 | NA | CR2 (20%/25%)/Rel (17%/22%) | MUDT | 33%/28% | 53%/52% at 3 yr | 39%/42% at 3 yr | 20%/23% at 3 yr | NA | 50%/44% at 3 yr | NA | ||
| Wang Y, et al. (6) | Yes | 231 | 28 | Inter- or high-risk AML in CR1 | Haplo-SCT | 36% | 42% at 1yr** | 15% at 3 yr | 13% at 3 yr | 76% at 3 yr | 79% at 3 yr | NA |
| 219 | 40 | Inter- or high-risk AML in CR1 | MSDT | 13% | 15% at 1yr | 15% at 3 yr | 8% at 3 yr | 80% at 3 yr | 82% at 3 yr | NA | ||
| Ruggeri A, et al. (64) | No | 360 | 44 | ≧CR2 (28%)/AD (38%)# | Haplo-SCT | 27% | 29% at 2yr | — | — | 32% at 2yr | — | NA |
| 558 | 45 | ≧CR2 (36%)/AD (19%) | UCBT | 31% | 24% at 2yr | HR=0.95 | HR=1.16 | 38% at 2yr | HR=0.78 | NA | ||
| Versluis J, et al. (65) | No | 3511 | 50 | Later CR (28%) | MSDT | 22% | 35% at 2yr | 32% at 2yr† | 15% at 2yr | 53% at 2yr | 59% at 2yr | NA |
| 1959 | 54 | Later CR (22%) | MUDT (10/10) | 26% | 30% at 2yr | 27% at 2yr | 20% at 2yr | 53% at 2yr | 59% at 2yr | NA | ||
| 549 | 52 | Later CR (26%) | MUDT (9/10) | 28% | 28% at 2yr | 31% at 2yr | 24% at 2yr | 44% at 2yr | 49% at 2yr | NA | ||
| 333 | 48 | Later CR (24%) | UCBT | 30% | 19% at 2yr | 30% at 2yr | 29% at 2yr | 41% at 2yr | 44% at 2yr†† | NA | ||
| 193 | 51 | Later CR (25%) | Haplo-SCT | 25% | 29% at 2yr | 22% at 2yr | 26% at 2yr | 52% at 2yr | 57% at 2yr | NA | ||
| Santoro N, et al. (66) | No | 250 | 65 | ≧CR2 (18%)/AD (44%)# | Haplo-SCT | 31% | 27% at 1yr | 28% at 1yr | 38% at 1yr | 35% at 1yr | 39% at 1yr | 30% at 1yr |
| 2589 | 64.8 | ≧CR2 (17%)/AD (30%) | MUDT | 33% | 41% at 1yr | 32% at 1yr | 28% at 1yr | 40% at 1yr | 42% at 1yr | 25% at 1yr | ||
| Baron F, et al. (62) | No | 701 | 58 | CR2 (14%) | MSDT | 19% | 50% at 2 yr | 32% at 2 yr | 13% at 2 yr | 54% at 2 yr | 59% at 2 yr | 29% at 2 yr |
| 611 | 62 | CR2 (20%) | MUDT | 30% | 51% at 2 yr | 30% at 2 yr | 20% at 2 yr | 50% at 2 yr | 56% at 2 yr | 23% at 2 yr | ||
| 112 | 58 | CR2 (34%) | Haplo-SCT | 31% | 30% at 2 yr | 34% at 2 yr | 22% at 2 yr | 50% at 2 yr | 53% at 2 yr | 37% at 2 yr | ||
| 291 | 55 | CR2 (39%) | UCBT | 38% | 28% at 2 yr | 34% at 2 yr | 16% at 2 yr | 44% at 2 yr | 43% at 2 yr | 39% at 2 yr | ||
| Salvatore D, et al. (67) | No | 185 | 50 | Inter (66%)/High (34%) | Haplo-SCT | 31% | 33% at 2 yr | 19% at 2 yr | 23% at 2 yr‡ | 58% at 2 yr‡ | 68% at 2 yr‡ | 47% at 2 yr |
| 2469 | 50 | Inter (76%)/High (24%) | MSDT | 21% | 35% at 2 yr | 24% at 2 yr | 10% at 2 yr | 67% at 2 yr | 76% at 2 yr | 50% at 2 yr | ||
| Rashidi A, et al. (61) | No | 336 | NA | Secondary (27%) | Haplo-SCT | 31% | 26% at 3yr | 38% at 3yr | 19% at 3yr | 43% at 3yr | 48% at 3yr | NA |
| 869 | NA | Secondary (24%) | MSDT | 26% | 56% at 3yr | 38% at 3yr | 14% at 3yr | 48% at 3yr | 55% at 3yr | NA | ||
| Ruggeri A, et al. (64) | No | 163 | 56 | CR1 (56%) | UCBT | 33% | 26% at 2 yr | 33% at 2 yr | 41% at 2 yr | 26% at 2 yr | 29% at 2 yr | 17% at 2 yr## |
| 246 | 60 | CR1 (44%) | Haplo-SCT | 23% | 26% at 2 yr | 30% at 2 yr | 34% at 2 yr | 36% at 2 yr | 41% at 2 yr | 28% at 2 yr | ||
| Brissot E, et al. (68) | No | 199 | 51.9 | Refractory (41%)/relapse (59%) | Haplo-SCT | 28.20% | 19.30% at 2 yr | 52% at 2 yr | 25% at 2 yr | 23% at 2 yr | 29% at 2 yr | 16% at 2 yr |
| 1111 | 52.4 | Refractory (45%)/relapse (55%) | MUDT | 30.60% | 25.60% at 2 yr | 46.30% at 2 yr | 25.70% at 2 yr | 28% at 2 yr | 34.70% at 2 yr | 16% at 2 yr | ||
| 383 | 51.7 | Refractory (37%)/relapse (63%) | MMUDT | 36.30% | 27.40% at 2 yr | 51.10% at 2 yr | 26.70% at 2 yr | 22.20% at 2 yr | 27.60% at 2 yr | 16% at 2 yr | ||
| Sanz J, et al. (69) | No | 215 | 48 | Inter (70%)/high (22%) | MSDT | 17% | 34% at 2 yr | 33% at 2 yr | 10% at 2 yr | 57% at 2 yr | 64% at 2 yr | 45% at 2 yr |
| 235 | 47 | Inter (60%)/high (34%) | MUDT | 28% | 32% at 2 yr | 25% at 2 yr | 14% at 2 yr | 62% at 2 yr | 68% at 2 yr | 42% at 2 yr | ||
| 789 | 54 | Inter (66%)/high (29%) | Haplo-SCT | 26% | 30% at 2 yr | 23% at 2 yr | 23% at 2 yr | 54% at 2 yr | 61% at 2 yr | 46% at 2 yr | ||
| Battipaglia G, et al. (63) | No | 389 | 52 | Refractory (42%)/relapse (58%) | Haplo-SCT | 28% | 27% at 2 yr | 50% at 2 yr | 31% at 2 yr | 19% at 2 yr | 25% at 2 yr | 18% at 2 yr |
| 1654 | 52 | Refractory (56%)/relapse (44%) | MSDT | 27% | 42% at 2 yr | 51% at 2 yr | 22% at 2 yr | 27% at 2 yr | 32% at 2 yr | 26% at 2 yr | ||
| Kharfan-Dabaja MA, et al. (70) | No | 135 | 44 | ≧CR2(45%)/Rel(55%) | Haplo-SCT | 27% at 180d | 22% at 2 yr | 48% at 2 yr | 27% at 2 yr | 29% at 2 yr | 29% at 2 yr | 19% at 2 yr |
| 320 | 46 | ≧CR2(50%)/Rel(50%) | MUDT | 30% at 180d | 32% at 2 yr | 56% at 2 yr | 26% at 2 yr | 25% at 2 yr | 31% at 2 yr | 21% at 2 yr | ||
| Konuma T, et al. (22) | No | 1102 | 51 | CR1(76%)/≧CR2(24%) | UCBT | 39% | 31% at 3 yr | 20% at 3 yr | 25% at 3 yr | 56% at 3 yr | 59% at 3 yr | 48% at 3 yr |
| 211 | 47 | CR1(76%)/≧CR2(24%) | Haplo-SCT | 30% | 37% at 3 yr | 22% at 3 yr | 21% at 3 yr | 58% at 3 yr | 59% at 3 yr | 43% at 3 yr |
AML, acute myeloid leukemia; haplo-SCT, haploidentical stem cell transplantation; Pros, prospective; Pt., patient; N, number; SCT, stem cell transplantation; GVHD, graft-versus-host disease; aGVHD, acute GVHD; cGVHD, chronic GVHD; NRM, nonrelapse mortality; LFS, leukemia-free survival; OS, overall survival; GRFS, GVHD and relapse-free survival; NA, not available; Rel, relapse; CR2, complete remission 2; MUDT, human leukocyte antigen (HLA)-matched unrelated donor transplantation; yr, year; MSDT, HLA-matched sibling donor transplantation; AD, advanced disease; UCBT, umbilical cord blood transplantation; HR, hazard ratio; MMUDT, mismatched MUDT; d, day.
*the median age of patients.
**indicates P<0.001 compared with that of MSDT.
@indicates that patients with poor-risk AML were enrolled in this study.
†indicates that haplo-SCT and MUDT (10/10) had lower CIRs than MSDT (P<0.01 for all).
††indicates that UCBT experienced lower RFS than MUDT (10/10), haplo-SCT and MSDT (P<0.01 for all).
#indicates that the percentages of patients in the haplo-SCT group with ≥CR2 or AD were higher than those of the MUDT group (P<0.0001) or the UCB group (P<0.0001).
‡indicates P<0.01 compared with that of MSDT.
##indicates P=0.02 compared with that of haplo-SCT.